Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
4.5
Journals
Biomedicines
Special Issues
Emerging Insights into HIV: Second Edition
share announcement

Emerging Insights into HIV: Second Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Microbiology in Human Health and Disease".

Deadline for manuscript submissions: 31 December 2026 | Viewed by 762

Editors

Dr. Konstantinos Protopapas

E-Mail Website
Guest Editor
4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Interests: HIV; PrEP; sexually transmitted infections; HIV/HCV co-infection; public health
Special Issues, Collections and Topics in MDPI journals
Dr. Antonios Papadopoulos

E-Mail
Guest Editor
4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Interests: HIV; infectious diseases; bone and joint infections; public health; emerging diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Charalampos D. Moschopoulos

E-Mail
Guest Editor
4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Interests: HIV; infectious diseases; viral infections; immunology; HIV neurocognitive disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue, entitled “Emerging Insights into HIV: Second Edition”. Despite the intensive research efforts, there is still no cure for HIV infection, and millions of people are affected worldwide. However, the advent of modern antiretroviral treatment has revolutionised the management of HIV, and consequently, people living with HIV are expected to have a near-normal life expectancy and quality of life. People on combined antiretroviral treatment achieve an undetectable plasma viral load and immune reconstitution. However, low-grade chronic inflammation renders them more susceptible to cardiometabolic and other comorbidities. This is intensified by the fact that people with HIV are getting older and developing comorbidities related to aging. In addition, people with HIV are still affected by stigma and discrimination, barriers to access to care, and socioeconomical and regional disparities, which provide additional obstacles to HIV prevention, treatment, and elimination.

This Special Issue aims to provide a comprehensive and up-to-date overview of the latest research and developments in the field of HIV pathogenesis and treatment. Moreover, it seeks to gather cutting-edge research and insights that contribute to the ongoing efforts to combat HIV, advance our understanding of HIV infection, and address global challenges, with a focus on global health equity.

Original research articles and reviews that align with the aim and scope of this Special Issue are welcome. Research areas may include, but are not limited to, the following: antiretroviral treatment and toxicities; novel antiretroviral treatment; HIV/HCV co-infection; HIV and COVID-19; HIV and comorbidities; AIDS-related illness and opportunistic infections; and HIV cures. Manuscripts should adhere to the journal’s guidelines for formatting and referencing.

In this Special Issue, we endorse the use of a person-centred language in all manuscripts.

We look forward to receiving your contributions.

Dr. Konstantinos Protopapas
Dr. Antonios Papadopoulos
Dr. Charalampos D. Moschopoulos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HIV/AIDS
  • antiretroviral treatment
  • comorbidities
  • co-infection
  • neuroHIV

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 1508 KB  
Article
Profile of People Living with HIV Switching Prior Antiretroviral Treatment to a Doravirine-Based Regimen in the Real-World Clinical Setting in Greece: The Retrospective DORAVITO Study
by Antonios Papadopoulos, Myrto Astriti, Vasileios Papastamopoulos, Vassileios Paparizos, Helen Sambatakou, Symeon Metallidis, Konstantinos Protopapas, Charalampos Moschopoulos, Georgios Adamis, Panagiota Lourida, Charisis Totsikas, Varvara Vasalou, Theofilos Chrysanthidis, Panagiotis Kollaras, Eleni Boutselakou, Dimitris Tsokos, Georgios Trimis and Lazaros Poughias
Biomedicines 2026, 14(8), 1761; https://doi.org/10.3390/biomedicines14081761 - 5 Aug 2026
Viewed by 265
Abstract
Background: Doravirine (DOR) is a new-generation non-nucleoside reverse transcriptase inhibitor, which has emerged as an option for people living with HIV (PLWH) owing to its favorable efficacy and safety profile, unique resistance pathway and limited potential for drug-drug interactions. Methods: This retrospective chart [...] Read more.
Background: Doravirine (DOR) is a new-generation non-nucleoside reverse transcriptase inhibitor, which has emerged as an option for people living with HIV (PLWH) owing to its favorable efficacy and safety profile, unique resistance pathway and limited potential for drug-drug interactions. Methods: This retrospective chart review study aimed to better understand DOR-based treatment use in Greece, PLWH characteristics, and drivers of treatment switch. Eligible individuals were adult PLWH who were switched to a DOR-based regimen based on the physician’s decision. Individuals exposed to DOR at any time prior to switching to the DOR-based regimen were excluded. Results: From 12 July 2023 to 31 October 2023, 110 PLWH were consecutively enrolled across 6 public hospital clinics. At baseline (closest prior to or on the date of first DOR prescription), the mean age of PLWH was 49.3 years, 90.9% were males, 88.2% were asymptomatic, 86.5% were virologically suppressed, 33.6% were suffering from multimorbidity (excluding infections/infestations), 45.5% were receiving comedications for their comorbidities, and 5.5% were co-infected with Hepatitis C virus. Most PLWH (98.2%) were prescribed DOR plus two nucleoside reverse transcriptase inhibitors; 87.3% were prescribed DOR/Lamivudine/Tenofovir Disoproxil Fumarate fixed-dose combination. PLWH started DOR a median of 11.7 years after first-ever antiretroviral therapy initiation, corresponding to 2nd/3rd/≥4th antiretroviral line in 33.6%/33.6%/32.7% of participants, respectively; 60.9% of them were proactively switched to a DOR-based regimen. The most common reasons for switching were ‘regimen simplification’ (42.7%), ‘tolerability’ (26.4%) and ‘prevention of toxicities’ (18.2%). Conclusions: This study highlights the patterns of DOR use in real-life clinical practice in Greece among treatment-experienced PLWH. Physicians switch HIV-1-infected individuals from prior ART to DOR-based regimens to offer a simplified regimen or to avoid or prevent toxicity. Full article
(This article belongs to the Special Issue Emerging Insights into HIV: Second Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop